MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "NMDA"

  • 2022 International Congress

    GRIN2D is a cause of autosomal dominant form of Parkinson’s disease

    A. Kishore, M. Sturm, J. Shin, S. Grover, F. Raimondi, C. Blauwendraat, S. Robert, G. Sarma, N. Casadei, P. Lichtner, A. Kumar-Sreelatha, J. Winkelmann, R. Krüger, A. Singleton, T. Gasser, P. Seth, J. Roeper, O. Riess, M. Sharma (Kochi, India)

    Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…
  • 2022 International Congress

    Isolated craniocervical dystonia without neuropsychiatric manifestations associated with NMDA-receptor antibodies

    S. Waller, L. Williams, A. Lee, MW. Lin, H. Morales-Briceno, V. Fung (Westmead, Australia)

    Objective: N-methyl-D-aspartate receptor (NMDAR) encephalitis classically spans neuropsychiatric disturbance, autonomic dysfunction and salient movement disorders. Attenuated presentations are increasingly recognised; however, presentations with an isolated…
  • MDS Virtual Congress 2021

    NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson’s Disease

    L. Gibson, T. Pollak, M. Hart, D. Trivedi, T. Nicholson, M. Zandi, K R. Chaudhuri, D. Aarsland (London, United Kingdom)

    Objective: To quantify the frequency of NMDA receptor (NMDAR) antibodies (Abs) in Parkinson’s disease (PD) and characterise their relationship with the cognitive and neuropsychiatric symptoms.…
  • MDS Virtual Congress 2020

    Movement disorders and it association with immunological causes: the key is in the movement

    E.M Gatto, G. Da Prat, J.L Etcheverry, M.E Cesarini, N. Gonzalez Rojas (CABA, Argentina)

    Objective: Observe the clinical and biochemical characteristics and the result of the treatment instituted in movement immune-mediated etiology. Background: Paraneoplastic autoimmune movement disorders are a…
  • MDS Virtual Congress 2020

    4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates

    T. Di Paolo, M. Bourque, R. Snodgrass (Quebec City, QC, Canada)

    Objective: This study investigated the antidyskinetic activity of 4-chlorokynurenine (AV-101) in parkinsonian monkeys with L-Dopa-induced dyskinesias. Background: The common treatment for Parkinson’s disease (PD) is L-Dopa…
  • 2019 International Congress

    Rapidly progressive cognitive decline and hemi-dystonia due to anti-neuronal surface antibodies

    F. Rolim, L. Mendes, P. Braga Neto, R. Sampaio, G. Ferreira, P. Nóbrega, V. Mesquita, F. Maia (Fortaleza, Brazil)

    Objective: To describe a case of marked asymmetric coarse tremor and dystonia in patient diagnosed with anti-NMDAR encephalitis. Background: Anti-NMDAR encephalitis has complex and heterogeneous…
  • 2019 International Congress

    Brain neurotransmitters and neuropeptides alternations in Parkinson’s induced mouse models

    N. Kumar, R. Khanna (Jaipur, India)

    Objective: Present study aimed to investigate the changes in brain neurotransmitters and neuropetides in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models  of PD. Background: Parkinson’s disease (PD), a…
  • 2018 International Congress

    Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

    V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

    Objective: We set out to evaluate potential neurorestorative effects of the GlyT1 inhibitor ACPPB vis-à-vis D-Serine in the intrastriatal 6-OHDA mouse model of Parkinson’s disease.…
  • 2018 International Congress

    An extraordinary cause of psychosis: Anti-NMDA receptor encephalitis

    H. Batur Caglayan, F. Sahin, T. Altıparmak, E. Turksoy, S. Candansayar, A. Bora Tokcaer (Ankara, Turkey)

    Objective: Anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis is an autoimmune encephalitis affecting predominantly young females. Background: It is characterized with neuropsychiatric symptoms, including personality changes, psychosis, autonomic…
  • 2018 International Congress

    Effects of N-methyl-D-aspartate receptor antagonist in Parkinson’s disease with dementia

    Y. Chung, I. Song, L. Lee (Incheon, Republic of Korea)

    Objective: We conducted this longitudinal study to confirm the efficacy of memantine for PDD by analyzing comparative changes in regional cerebral blood flow (rCBF) and…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley